Data as of Aug 29
| +0.04 / +0.42%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 13.00, with a high estimate of 24.00 and a low estimate of 4.50. The median estimate represents a +36.84% increase from the last price of 9.50.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.